Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). Key applications of this technology include:
The Sengenics AxCESS research service packages feature three KREX-based functional protein arrays developed for high-throughput and cost-effective immuno-proteomics applications. These protein arrays utilise the patented KREX protein folding technology for the production of full-length, correctly folded and functional proteins.
This range of arrays provide easy access to Sengenics’ KREX technology to enable high-specificity autoantibody characterisation with a focus on autoimmune, cancer and neurodegenerative disorders. All packages are carried out on a standard “fee-for-service” basis that include running of assays with integrated bioinformatics analysis and reporting.
Sengenics AxCESS arrays:
Immunome AxCESS array
Contains over 1600 correctly folded and functional human proteins spotted in duplicate. Screen up to 2 samples per slide. Key applications include:
CTA AxCESS array
Contains over 200 correctly folded and functional CT antigens spotted in duplicate. Screen up to 8 samples per slide. Key applications include:
OncoREX p53 AxCESS array
Contains over 100 correctly folded and functional wild type and mutant p53 spotted in duplicate. Screen up to 8 samples per slide. Key applications include:
Sengenics has not received any reviews.
Sengenics has not received any endorsements.